Skip to content Skip to footer
Subscribe Now
Viewpoints_Caterina Brindicci
VIEWPOINTS

Enhancing Autoimmune Care: Caterina Brindicci from AstraZeneca in a Riveting Conversation with PharmaShots

Shots:  SLE-related diseases like CLE and IIM are characterized by strong type I interferon involvement. The proven efficacy of Saphnelo (anifrolumab) in SLE lays the foundation for its potential use in CLE and IIM Recently, AstraZeneca initiated two new P-III trials, LAVENDER and JASMINE, to evaluate Saphnelo in cutaneous lupus erythematosus and idiopathic inflammatory myopathies …
March 3, 2025

Read more

VIEWPOINTS_Micki Hultquist_2024
VIEWPOINTS

AstraZeneca at ACR 2023: Micki Hultquist Shares Post-hoc Analysis of Saphnelo

Shots: AstraZeneca at ACR 2023 presented 18 abstracts from its respiratory and immunology pipelines Micki Hultquist in a stimulating conversation with PharmaShots sheds light on Saphnelo, AstraZeneca’s first-in-class biologic treatment for systemic lupus erythematosus (SLE) The post-hoc analysis of the TULIP P-III program reveals that the patients showcased more frequent and sustained remission as compared…
February 5, 2024

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]